Innovative drugs surge: Is earnings growth driving a sector value revaluation?
Innovative drugs surge: Is earnings growth driving a sector value revaluation? Today, Hong Kong-listed innovative drug stocks rallied sharply, with WuXi XDC soaring over 14%, Asymchem jumping 16.83%, and Insilico Medicine rising 12.87%. On the news front, WuXi XDC and Asymchem just released their interim 2026 results. For WuXi XDC, first-half revenue reached RMB 3.701 billion, up 37.0% year-on-year, in line with market expectations; net profit attributable to shareholders was RMB 819 million, up 9.9%; adjusted net profit attributable to shareholders was RMB 1.027 billion, up 37.4%, essentially matching revenue growth and indicating sound earnings quality. Gross margin was 37.0%, up 0.9 percentage points year-on-year. Order backlog remained robust, with unfilled service orders of approximat
Biotech Rallies in Hong Kong as BD Deals Accelerate
On April 1, the Hang Seng Biotech Index surged 6.78% in a single day, followed by another 0.89% gain on April 2, closing at 15,641. From the ETF side, funds tracking healthcare and biotech moved higher in sync with the index. $CAM HSBIOTECH(03069)$ rose 0.58%, $CSOP HSBIOTECH(03174)$ gained 0.92%, and $GX CN BIOTECH(02820)$ increased 1.17%, showing a consistent upward trend alongside the broader sector. Capital allocation into passive products is also picking up. At the stock level, $HANSOH PHARMA(03692)$ rose 5.18%, $INNOCARE(09969)$ gained 4.44%,
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.